Functional Consequences of a Polymorphism Affecting NF-κB p50-p50 Binding to the TNF Promoter Region
- 1 December 2000
- journal article
- research article
- Published by Taylor & Francis in Molecular and Cellular Biology
- Vol. 20 (24) , 9113-9119
- https://doi.org/10.1128/mcb.20.24.9113-9119.2000
Abstract
Stimulation of the NF-κB pathway often causes p65-p50 and p50-p50 dimers to be simultaneously present in the cell nucleus. A natural polymorphism at nucleotide −863 in the human TNF promoter (encoding tumor necrosis factor [TNF]) region provides an opportunity to dissect the functional interaction of p65-p50 and p50-p50 at a single NF-κB binding site. We found that this site normally binds both p65-p50 and p50-p50, but a single base change specifically inhibits p50-p50 binding. Reporter gene analysis in COS-7 cells expressing both p65-p50 and p50-p50 shows that the ability to bind p50-p50 reduces the enhancer effect of this NF-κB site. Using an adenoviral reporter assay, we found that the variant which binds p50-p50 results in a reduction of lipopolysaccharide-inducible gene expression in primary human monocytes. This finding adds to a growing body of experimental evidence that p50-p50 can inhibit the transactivating effects of p65-p50 and illustrates the potential for genetic modulation of inflammatory gene regulation in humans by subtle nucleotide changes that alter the relative binding affinities of different forms of the NF-κB complex.Keywords
This publication has 31 references indexed in Scilit:
- Complex NF-κB Interactions at the Distal Tumor Necrosis Factor Promoter Region in Human MonocytesJournal of Biological Chemistry, 1998
- Polymorphism of the 5′‐flanking region of the human tumor necrosis factor (TNF)‐α gene in JapaneseTissue Antigens, 1998
- THE NF-κB AND IκB PROTEINS: New Discoveries and InsightsAnnual Review of Immunology, 1996
- Virus induction of human IFNβ gene expression requires the assembly of an enhanceosomeCell, 1995
- Targeted disruption of the p50 subunit of NF-κB leads to multifocal defects in immune responsesCell, 1995
- Repeated therapy with monoclonal antibody to tumour necrosis factor α (cA2) in patients with rheumatoid arthritisThe Lancet, 1994
- An HMG-like protein that can switch a transcriptional activator to a repressorNature, 1994
- KBF1 (p50 NF-kappa B homodimer) acts as a repressor of H-2Kb gene expression in metastatic tumor cells.The Journal of Experimental Medicine, 1993
- Endotoxin-responsive sequences control cachectin/tumor necrosis factor biosynthesis at the translational level.The Journal of Experimental Medicine, 1990
- A conserved AU sequence from the 3′ untranslated region of GM-CSF mRNA mediates selective mRNA degradationCell, 1986